Anti-angiogenesis and metastasis: A tumour and stromal cell alliance

Journal of Internal Medicine

Volumn 273, Issue 2, 2013, Pages 128-137

  Moserle, L ^a   Casanovas, O ^a  

^a Hereditari Cancer Program   (Spain)

Author keywords

Anti angiogenic therapy; Hypoxia; Tumour invasion; Tumour metastasis; Tumour stroma; VEGF

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CRIZOTINIB; PF 04217903; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; COLON CANCER; DRUG WITHDRAWAL; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANOXIA; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872517083     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12018     Document Type: Review

References (67)

1. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69(Suppl 3): 4-10.
2. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Onco 2011; 8: 210-21.
3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
4. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
5. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
6. Sennino B, Ishiguro-Oonuma T, Wei Y et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2: 270-87.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
9. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med (Berl) 2008; 86: 135-44.
10. Xian X, Hakansson J, Stahlberg A et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006; 116: 642-51.
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
12. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-7.
13. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-91.
14. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010; 46: 1323-32.
15. Michieli P. Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle 2009; 8: 3291-6.
16. Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 2009; 12: 74-80.
17. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008; 5: 194-204.
18. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009; 6: 395-404.
19. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007; 26: 223-4.
20. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16: 5928-35.
21. De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8: 393-404.
22. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
23. Demir R, Naschberger L, Demir I et al. Hypoxia generates a more invasive phenotype of tumour cells: an in vivo experimental setup based on the chorioallantoic membrane. Pathol Oncol Res 2009; 15: 417-22.
24. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-61.
25. Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009; 280: 1-14.
26. Lu KV, Chang JP, Parachoniak CA et al. VEGF inhibits tumor cell invasion and Mesenchymal transition through a MET/VEGFR2 Complex. Cancer Cell 2012; 22: 21-35.
27. Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett 2012; 320: 48-55.
28. Ide T, Kitajima Y, Miyoshi A et al. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer 2006; 119: 2750-9.
29. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
30. Cox EA, Sastry SK, Huttenlocher A. Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases. Mol Biol Cell 2001; 12: 265-77.
31. Ilina O, Friedl P. Mechanisms of collective cell migration at a glance. J Cell Sci 2009; 122: 3203-8.
32. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011; 147: 992-1009.
33. Madsen CD, Sahai E. Cancer dissemination-lessons from leukocytes. Dev Cell 2010; 19: 13-26.
34. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011; 1: 482-97.
35. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-52.
36. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010; 29: 243-8.
37. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
38. Bautch VL. Endothelial cells form a phalanx to block tumor metastasis. Cell 2009; 136: 810-2.
39. Mazzone M, Dettori D, Leite de Oliveira R et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136: 839-51.
40. Maione F, Capano S, Regano D et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest 2012; 122: 1832-48.
41. Maione F, Molla F, Meda C et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 2009; 119: 3356-72.
42. Subarsky P, Hill RP. Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells. Clin Exp Metastasis 2008; 25: 253-64.
43. Blouw B, Song H, Tihan T et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4: 133-46.
44. Casazza A, Kigel B, Maione F et al. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med 2012; 4: 234-50.
45. Moserle L, Casanovas O. Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer. EMBO Mol Med 2012; 4: 168-70.
46. Chung AS, Kowanetz M, Wu X et al. Differential drug-class specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 2012; 227: 404-16.
47. Singh M, Couto SS, Forrest WF et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumor models. J Pathol 2012; 227: 417-30.
48. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-95.
49. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-52.
50. Saharinen P, Alitalo K. Double target for tumor mass destruction. J Clin Invest 2003; 111: 1277-80.
51. Faris JE, Michaelson MD. Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC. Nat Rev Clin Oncol 2009; 7: 7-8.
52. Hotte SJ, Bjarnason GA, Heng DY et al. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Curr Oncol 2011; 18(Suppl 2): S11-9.
53. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-45.
54. Rosner I, Bratslavsky G, Pinto PA, Linehan WM. The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 2009; 27: 131-6.
55. Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999; 154: 693-703.
56. Brat DJ, Kaur B, Van Meir EG. Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 2003; 8: d100-16.
57. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5: 610-20.
58. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009; 91: 329-36.
59. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
60. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
61. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-56.
62. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8.
63. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 2009; 115: 1859-66.
64. Miles D, Harbeck N, Escudier B et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29: 83-8.
65. Potemski P. Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials? J Clin Oncol 2011; 29: e384-5; author reply e6.
66. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B et al. Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 2010; 10: 537-42.
67. Martinez-Outschoorn UE, Lin Z, Trimmer C et al. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle 2011; 10: 2504-20.